{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:27:02Z","timestamp":1774438022454,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,1,15]],"date-time":"2009-01-15T00:00:00Z","timestamp":1231977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00198-008-0827-4","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T10:37:40Z","timestamp":1231929460000},"page":"1595-1601","source":"Crossref","is-referenced-by-count":13,"title":["Monthly ibandronate suppresses serum CTX-I within 3\u00a0days and maintains a monthly fluctuating pattern of suppression"],"prefix":"10.1007","volume":"20","author":[{"given":"N.","family":"Binkley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Kohles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Sunyecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,15]]},"reference":[{"key":"827_CR1","first-page":"115","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115\u2013137","journal-title":"Endocr Rev"},{"key":"827_CR2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"827_CR3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1185\/030079905X49635","volume":"21","author":"AK Srivastava","year":"2005","unstructured":"Srivastava AK, Vliet EL, Lewiecki EM et al (2005) Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21:1015\u20131026","journal-title":"Curr Med Res Opin"},{"key":"827_CR4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/gme.0b013e31815f8917","volume":"15","author":"M Gass","year":"2008","unstructured":"Gass M, Kagan R, Kohles J et al (2008) Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15:667\u2013675 (PMID: 18327152)","journal-title":"Menopause"},{"key":"827_CR5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jocd.2008.02.004","volume":"11","author":"AI Sebba","year":"2008","unstructured":"Sebba AI, Broy S, Kohles JD et al (2008) Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naive population. J Clin Densitom 11:417\u2013423 (PMID: 18456528)","journal-title":"J Clin Densitom"},{"key":"827_CR6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.bone.2007.01.016","volume":"40","author":"K Saag","year":"2007","unstructured":"Saag K, Lindsay R, Kriegman A et al (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238\u20131243","journal-title":"Bone"},{"key":"827_CR7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"827_CR8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00228-006-0174-3","volume":"62","author":"DJ Leeming","year":"2006","unstructured":"Leeming DJ, Alexandersen P, Karsdal MA et al (2006) An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 62:781\u2013792","journal-title":"Eur J Clin Pharmacol"},{"key":"827_CR9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","volume":"80","author":"RR Recker","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856\u2013861","journal-title":"Mayo Clin Proc"},{"key":"827_CR10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"827_CR11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","volume":"92","author":"PD Delmas","year":"2007","unstructured":"Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296\u20131304","journal-title":"J Clin Endocrinol Metab"},{"key":"827_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","volume":"21","author":"CH Chesnut","year":"2005","unstructured":"Chesnut CH, Ettinger MP, Miller PD et al (2005) Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 21:391\u2013401","journal-title":"Curr Med Res Opin"},{"key":"827_CR13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"827_CR14","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1210\/jc.2005-2602","volume":"91","author":"S Bonnick","year":"2006","unstructured":"Bonnick S, Saag KG, Kiel DP et al (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631\u20132637","journal-title":"J Clin Endocrinol Metab"},{"key":"827_CR15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s001980070083","volume":"11","author":"L Raisz","year":"2000","unstructured":"Raisz L, Smith JA, Trahiotis M et al (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615\u2013620","journal-title":"Osteoporos Int"},{"key":"827_CR16","unstructured":"National Osteoporosis Foundation. Physician\u2019s guide to prevention and treatment of osteoporosis. Available at http:\/\/www.nof.org\/physguide\/pharmacologic.htm . Accessed August 7, 2007"},{"key":"827_CR17","unstructured":"Serum CrossLaps\u00ae ELISA package insert. Nordic Bioscience Diagnostics A\/S, Herlev, Denmark"},{"key":"827_CR18","unstructured":"Quidel Metra BAP EIA Kit, package insert. Quidel, San Diego, CA"},{"key":"827_CR19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"827_CR20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","volume":"6","author":"EM Lewiecki","year":"2003","unstructured":"Lewiecki EM (2003) Nonresponders to osteoporosis study. J Clin Densitom 6:307\u2013314","journal-title":"J Clin Densitom"},{"key":"827_CR21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","volume":"24","author":"P Ravn","year":"1999","unstructured":"Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237\u2013244","journal-title":"Bone"},{"key":"827_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jocd.2006.05.002","volume":"9","author":"N Binkley","year":"2006","unstructured":"Binkley N, Bilezikian JP, Kendler DL et al (2006) Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9:4\u201314","journal-title":"J Clin Densitom"},{"key":"827_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF02938621","volume":"5","author":"PD Miller","year":"2007","unstructured":"Miller PD (2007) Monitoring osteoporosis therapies. Curr Osteoporos Rep 5:38\u201343","journal-title":"Curr Osteoporos Rep"},{"key":"827_CR24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","volume":"89","author":"JA Clowes","year":"2004","unstructured":"Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117\u20131123","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-008-0827-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0827-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:01:01Z","timestamp":1558623661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0827-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,15]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0827-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,15]]}}}